+1-518-621-2074 | US-Canada Toll Free Contact Us

U.S. Onychomycosis Market to Benefit from Rising Occurrence of Peripheral Artery Disease (PAD)

about us

Published on : Aug 11, 2016

ALBANY, New York, August 11, 2016: Among the several nail diseases or abnormalities, onychomycosis is the most commonly found. Around 50% of all nail abnormalities around the world are cases of onychomycosis. Although onychomycosis is not life-threatening, it can get worse if not treated on time. Changes in the color or appearance of the nail, pain, discomfort, and interference while standing, exercising, and walking are some of the common symptoms of onychomycosis. Distal subungual onychomycosis, proximal subungual onychomycosis, candidal onychomycosis, white superficial onychomycosis, and endonyx onychomycosis are the common types of onychomycosis. The rising occurrence of onychomycosis is expected to propel the U.S. market for the therapeutics for the same. These are some of the vital findings of a new report added by ResearchMoz.us to its database.

The report, titled ‘The US Onychomycosis Market: Size, Trends & Forecasts (2016-2020),’ states that the market is predicted to expand significantly during the period between 2016 and 2020 owing to the rising occurrence of peripheral artery diseases, the growing aging population, and the rising diabetic population. The increasing per-capita healthcare expenditure is also anticipated to benefit the U.S. onychomycosis market in the coming years, predict the analysts. 

The research also briefs readers about the many challenges faced by key companies operating in the market. The lack of reimbursement policies and awareness regarding the available treatments for onychomycosis is anticipated to hamper the market for onychomycosis in the United States. However, the rising prevalence of onychomycosis in children will benefit the market in the U.S., state the analysts. 

Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=760229

The research focuses on the various treatments available for onychomycosis. Topical treatments and oral treatments are increasingly being used to treat onychomycosis. Oral treatment for onychomycosis comprises itraconazole, terbinafine, and others, while topical treatments include jublia, kerydin, and others. Key companies operating in the U.S. onychomycosis market are concentrating on introducing new treatments and medicines to cure onychomycosis. Non-pharmacologic approaches such as photodynamic therapy and laser treatment are also being used to treat onychomycosis. 
Valeant Pharmaceuticals, Anacor Pharmaceuticals, Johnson & Johnson, and Novartis AG are some of the key companies operating in the U.S. onychomycosis market. With the introduction of new non-pharmacological approaches, medicines, and treatments the market for onychomycosis in the U.S. is predicted to be highly promising for the new participants in the coming years. The U.S. onychomycosis market is thus anticipated to register healthy growth in the years to come. 

As per the findings of the research report, the combination of laser treatment and topical antifungal treatment is expected to emerge as an effective way to treat onychomycosis. Key companies are therefore focusing on introducing a combined treatment. As diseases in nails have become common among the elderly, research is being done by key organizations for introducing new drugs and treatments aimed at the geriatric demographic. 

With rising government funding, drug developers are expected to discover more varieties of drugs to treat onychomycosis. This is predicted to propel the market in the U.S. 

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]